Business Context and Reporting Period
This Form 8-K Current Report was filed by Ocuphire Pharma, Inc. (OCUP) on December 5, 2023, covering events occurring on December 1, 2023. The filing primarily addresses the appointment of a new senior executive officer and the amendment of his employment agreement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to executive compensation terms:
- Base Salary: $350,000 annually, with a potential increase to $400,000 upon specific milestones.
- Incentive Compensation: Targeted at 45% of base salary.
- Equity Grants: 74,538 incentive stock options and 49,692 restricted stock units (RSUs).
Material Changes
The material change reported is the promotion of Ronil Patel to Chief Business Officer, effective December 1, 2023. This appointment is accompanied by a First Amendment to his employment agreement, which adjusts his compensation package and grants new equity awards.
Outlook, Risks, and Unusual Items
Management Commentary and Milestones: The amended agreement includes salary increase triggers tied to strategic transactions (minimum $1 million gross proceeds), unrestricted cash balances of at least $100 million, or the successful completion of the first batch of drug product for candidate APX3330 for Phase 3 trials.
Severance Provisions: In the event of termination for "Good Reason," Mr. Patel is entitled to severance equal to 0.75 times the sum of his current base salary and prorated cash bonus, plus continued COBRA coverage.
Risks and Contingencies: The Company has entered into a standard indemnification agreement, which may require the Company to indemnify Mr. Patel for expenses, judgments, fines, and settlement amounts arising from his service to the Company.
Investor Verification Checklist
- Verify the vesting schedule for the 74,538 stock options and 49,692 RSUs granted to Mr. Patel (25% at 6 months, remainder over 2 years).
- Monitor progress on the APX3330 Phase 3 clinical trial batch completion, as this is a trigger for salary increase.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.1) and First Amendment (Exhibit 10.2) for detailed definitions of "Good Reason" and "Cause."
- Confirm the Company's current unrestricted cash balance to assess proximity to the $100 million salary trigger.